Company intelligence / Profile preview

EyeDura Therapeutics, Inc.

Ownership
Private
Development stage
Other
01

Overview

EyeDura is developing preservative-free sustained release eye drops with a proprietary topical drug delivery platform. Their drug formulation is lipid-based, has high viscosity, and integrates into the lipid phase of the tear film with zero-order kinetics drug release.

Therapeutic areas
Ophthalmology
Modalities
Lipid-based drug formulations
Industry
Biotech
02

Drug pipeline

1 asset

EYED-002

2

Beyond the preview

Go deeper on EyeDura Therapeutics, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on EyeDura Therapeutics, Inc..

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call